I. MODIFIED AGREEMENTS

Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Change from original
agreement

Terms/Details (Date)

Acambis plc
(UK; ACAM)

Novartis AG
(Switzerland)

Novartis agreed to pay $19M to settle a dispute related to the Arilvax yellow fever vaccine

Acambis had accused Chiron Corp., since acquired by Novartis, of non-performance under their 1999 agreement; Acambis has U.S. rights to the product, and gained an exclusive worldwide option under the new deal (9/12)

Enzo
Biochem Inc.
(NYSE:ENZ)

Sigma-Aldrich Corp.

They settled a lawsuit filed by Enzo related to labeled nucleotide technology

Terms were not disclosed; Enzo has similar patent infringement lawsuits pending with several other companies (9/19)

ImClone
Systems Inc.
(IMCL)

Merck KGaA (Germany)

They amended deal from 1998 covering Erbitux and certain other work in the field of EGFR-targeted antibodies

ImClone consented to Merck's sublicense of certain anti-EGFR antibody rights to Takeda Pharmaceutical Co.; ImClone gets |7.5M for that deal; also, its Erbitux royalties on sales outside the U.S. and Canada were increased to 9% (7/20)

I. TERMINATED AGREEMENTS

IDEA AG*
(Germany)

McNeil Consumer & Specialty Pharmaceuticals (unit of Johnson & Johnson)

IDEA reacquired North American rights to IDEA-033, giving it worldwide rights to the analgesic product

McNeil licensed rights to the product in 2003; terms of the reacquisition were not disclosed (8/2)

PDL
BioPharma
Inc. (PDLI)

Hoffmann- La Roche Inc.

Roche ended its involvement in the development of daclizumab for asthma, a deal started in 2004

The companies continue a deal to develop the product in transplant indications; PDL regained all rights in asthma (8/30)

Speedel AG
(Switzerland;
SWX:SPPN)

Abbott Laboratories

Abbott declined to exercise its license-back option for SPP200

Speedel retains all rights to the product, a long-acting direct thrombin inhibitor that has completed Phase II trials (8/16)

Symbollon
Pharmaceuticals
Inc. (OTC BB:
SYMBA)

Gardent Pharmaceuticals Inc. (formerly Bioaccelerate Holdings Inc.)

They terminated worldwide deal covering use of IoGen for treating pain and tenderness associated with fibrocystic breast disease

Gardent was to have funded Phase III trials; Symbollon regained all rights to the product (8/24)

Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange.